請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51617
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊曜宇(Eric Y. Chuang) | |
dc.contributor.author | Yu-Ching Hsu | en |
dc.contributor.author | 徐于晴 | zh_TW |
dc.date.accessioned | 2021-06-15T13:41:23Z | - |
dc.date.available | 2016-02-15 | |
dc.date.copyright | 2016-02-15 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2016-01-06 | |
dc.identifier.citation | 1. Cowell JK, Hawthorn L: The Application of Microarray Technology to the Analysis of the Cancer Genome. Current Molecular Medicine 2007, 7:18.
2. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi O-P: Molecular Cytogenetics of Primary Breast Cancer by CGH. Genes, Chromosomes & Cancer 1998, 21:8. 3. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I, Schwendel A: Patterns of Chromosomal Imbalances in Invasive Breast Cancer. International Journal of Cancer 2000, 89(3):305-310. 4. Negrini S, Gorgoulis VG, Halazonetis TD: Genomic Instability--an Evolving Hallmark of Cancer. Nature Reviews Molecular Cell Biology 2010, 11(3):220-228. 5. Lengauer C, Kinzler KW, Vogelstein B: Genetic Instabilities in Human Cancers. Nature 1998, 396:643-649. 6. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sorlie T, Borgen E, Rye IH, Langerod A et al: Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients. Science Translational Medicine 2010, 2(38):38ra47. 7. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA: The Order of Genetic Events Associated with Colorectal Cancer Progression Inferred from Meta-analysis of Copy Number Changes. Genes, Chromosomes & Cancer 2006, 45(1):31-41. 8. Massion PP, Kuo W-L, Stokoe DS, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D et al: Genomic Copy Number Analysis of Non-small Cell Lung Cancer Using Array Comparative Hybridization Implications of the Phosphotidylinositol 3-kinase Pathway. Cancer Research 2002, 62:3636-3640. 9. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg Å, Isola JJ: Frequent Amplificaiton of Chromosomal Region 20q12-q13 in Ovarian Cancer. Clinical Cancer Research 2000, 6:1833-1839. 10. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T et al: Genomic and Transcriptional Aberrations Linked to Breast Cancer Pathophysiologies. Cancer Cell 2006, 10(6):529-541. 11. Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, Ried T, Gaiser T: Chromothripsis and Focal Copy Number Alterations Determine Poor Outcome in Malignant Melanoma. Cancer Research 2013, 73(5):1454-1460. 12. Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y, Mackey JR, Damaraju S: Germline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence. PloS One 2013, 8(1):e53850. 13. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A et al: Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer. Cancer Research 2002, 62:6. 14. Loo LWM, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI et al: Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes. Cancer Research 2004, 64:9. 15. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN et al: Breast Tumor Copy Number Aberration Phenotypes and Genomic Instability. BMC Cancer 2006, 6:96. 16. Persson K, Pandis N, Mertens F, Borg A, Baldetorp B, Killander D, Isola J: Chromosomal Aberrations in Breast Cancer: A Comparison Between Cytogenetics and Comparative Genomic Hybridization. Genes, Chromosomes & Cancer 1999, 25:8. 17. Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N, Waldman FM: Genetic Alterations in Lobular Breast Cancer by Comparative Genomic Hybridization. International Journal of Cancer 1997, 74:5. 18. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. Science 1992, 258:4. 19. Muleris M, Almeida A, Gerbault-Seureau M, Malfoy B, Dutrillaux B: Detection of DNA Amplification in 17 Primary Breast Carcinomas With Homogeneously Staining Regions by a Modified Comparative Genomic Hybridization Technique. Genes, Chromosomes & Cancer 1994, 10:11. 20. Isola JJ, Kallioniemi O-P, Chu LW, Fuqua SAW, Hilsenbeck SG, Osborne CK, Waldman FM: Genetic Aberrations Detected by Comparative Genomic Hybridization Predict Outcome in Node-Negative Breast Cancer. American Joarnal of Pathology 1995, 147:7. 21. LISITSYN NA, LISITSINA NM, DALBAGNI G, BARKER P, SANCHEZ CA, GNARRA J, LINEHAN WM, REID BJ, WIGLER MH: Comparative Genomic Analysis of Tumors: Detection of DNA Losses and Amplification. Proceedings of the National Academy of Sciences 1995, 92:5. 22. Courjal F, Theillet C: Comparative Genomic Hybridization Analysis of Breast Tumors with Predetermined Profiles of DNA Amplification. Cancer Research 1997, 7:10. 23. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo W-L, Chen C, Zhai Y et al: High Resolution Analysis of DNA Copy Number Variation Using Comparative Genomic Hybridization to Microarrays. Nature Genetics 1998, 20:5. 24. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C et al: Subtypes of Familial Breast Tumours Revealed by Expression and Copy Number Profiling. Breast Cancer Research and Treatment 2010, 123(3):661-677. 25. Al-Lazikani B, Banerji U, Workman P: Combinatorial Drug Therapy for Cancer in the Post-genomic Era. Nature biotechnology 2012, 30(7):679-692. 26. Ryall KA, Tan AC: Systems Biology Approaches for Advancing the Discovery of Effective Drug Combinations. Journal of Cheminformatics 2015, 7:7. 27. Garraway LA, Janne PA: Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery 2012, 2(3):214-226. 28. Xu KJ, Song J, Zhao XM: The Drug Cocktail Network. BMC Systems Biology 2012, 6 Suppl 1:S5. 29. Huang L, Li F, Sheng J, Xia X, Ma J, Zhan M, Wong ST: DrugComboRanker: Drug Combination Discovery Based on Target Network Analysis. Bioinformatics 2014, 30(12):i228-236. 30. Juan H-F, Huang H-C: Systems Biology : Applications in Cancer-related Research. New Jersey: World Scientific; 2012. 31. Yang J, Tang H, Li Y, Zhong R, Wang T, Wong S, Xiao G, Xie Y: DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects. CPT: Pharmacometrics & Systems Pharmacology 2015, 4. 32. Goswami CP, Cheng L, Alexander P, Singal A, Li L: A New Drug Combinatory Effect Prediction Algorithm on the Cancer Cell Based on Gene Expression and Dose-Response Curve. CPT: Pharmacometrics & Systems Pharmacology 2015, 4. 33. Zhao J, Zhang XS, Zhang S: Predicting Cooperative Drug Effects through the Quantitative Cellular Profiling of Response to Individual Drugs. CPT Pharmacometrics Syst Pharmacol 2014, 3:e102. 34. Justin L: The Connectivity Map : a New Tool for Biomedical Research. Nature 2007, 7:7. 35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al: Gene Set Enrichment Analysis: a Knowledge-based Approach for Interpreting Genome-wide Expression Profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(43):15545-15550. 36. Nam D, Kim SY: Gene-set Approach for Expression Pattern Analysis. Briefings in Bioinformatics 2008, 9(3):189-197. 37. Fridley BL, Biernacka JM: Gene Set Analysis of SNP Data: Benefits, Challenges, and Future Directions. European Journal of Human Genetics : EJHG 2011, 19(8):837-843. 38. Hung JH, Yang TH, Hu Z, Weng Z, DeLisi C: Gene Set Enrichment Analysis: Performance Evaluation and Usage Guidelines. Briefings In Bioinformatics 2012, 13(3):281-291. 39. Hsu Y-C, Chiu Y-C, Chen Y, Hsiao T-H, Chuang EY: A Gene-set Approach to Analyze Copy Number Alterations in Breast Cancer. Translational Cancer Research 2015, 4(3):291-302. 40. deGraffenried LA, Russell DH, Middleton AK, Roth RA, Donzis EJ, Friedrichs WE, Silva JM, Hidalgo M: Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity. Clinical Cancer Research 2004, 10:8. 41. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA: Dual Inhibition of mTOR and Estrogen Receptor Signaling In Vitro Induces Cell Death in Models of Breast Cancer. Clinical Cancer Research 2005, 11:10. 42. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE: Inhibition of Histone Deacetylase Overcomes Rapamycin-mediated Resistance in Diffuse Large B-cell Lymphoma by Inhibiting Akt Signaling through mTORC2. Blood 2009, 114(14):2926-2935. 43. Xiao Y, Hsiao TH, Suresh U, Chen HI, Wu X, Wolf SE, Chen Y: A Novel Significance Score for Gene Selection and Ranking. Bioinformatics 2014, 30(6):801-807. 44. Chen H-IH, Hsiao T-H, Chen Y, Keller C: S-score : a Novel Scoring Method of Gene Signatures for Molecular Classification. IEEE 2011:4. 45. Hsiao TH, Chen HI, Lu JY, Lin PY, Keller C, Comerford S, Tomlinson GE, Chen Y: Utilizing Signature-score to Identify Oncogenic Pathways of Cholangiocarcinoma. Translational Cancer Research 2013, 2(1):6-17. 46. Bansal M, Yang J, Karran C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R et al: A Community Computational Challenge to Predict the Activity of Pairs of Compounds. Nature Computational Biology 2014, 32. 47. Baudis M: Genomic Imbalances in 5918 Malignant Epithelial Tumors: an Explorative Meta-analysis of Chromosomal CGH Data. BMC Cancer 2007, 7:226. 48. Tsarouha H, Pandis N, Bardi G, Teixeira MR, Andersen JA, Heim S: Karyotypic Evolution in Breast Carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the Primary Chromosome Abnormality. Cancer Genet Cytogenet 1999, 113:156-161. 49. Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C: NOTCH-1 and NOTCH-4 are Novel Gene Targets of PEA3 in Breast Cancer: Novel Therapeutic Implications. Breast Cancer Research : BCR 2011, 13(3):R63. 50. Gong T, Xuan J, Chen L, Riggins RB, Li H, Hoffman EP, Clarke R, Wang Y: Motif-Guided Sparse Decomposition of Gene Expression Data for Regulatory Module Identification. BMC Bioinformatics 2011, 12:82. 51. He Q, Liang CH, Lippard SJ: Steroid Hormones Induce HMG1 Overexpression and Sensitize Breast Cancer Cells to Cisplatin and Carboplatin. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(11):5768- 5772. 52. Maeda T, Maeda M, Stewart AFR: TEF-1 Transcription Factors Regulate Activity of the Mouse Mammary Tumor Virus LTR. Biochemical and Biophysical Research Communications 2002, 296:1279-1285. 53. Nguyen A, Rosner A, Milovanovic T, Hope C, Planutis K, Saha B, Chaiwun B, Lin F, Imam SA, Marsh JL et al: Wnt Pathway Component LEF1 Mediates Tumor Cell Invasion and Is Expressed in Human and Murine Breast Cancers Lacking ErbB2(her-2/neu) Overexpression. International Journal of Oncology 2005, 27:949-956. 54. Nguyen-Vu T, Vedin LL, Liu K, Jonsson P, Lin JZ, Candelaria NR, Candelaria LP, Addanki S, Williams C, Gustafsson JA et al: Liver X Receptor Ligands Disrupt Breast Cancer Cell Proliferation through an E2F-mediated mechanism. Breast Cancer Research : BCR 2013, 15(3):R51. 55. Wang X, Southard RC, Allred CD, Talbert DR, Wilson ME, Kilgore MW: MAZ Drives Tumor-specific Expression of PPAR Gamma 1 in Breast Cancer Cells. Breast Cancer Research and Treatment 2008, 111(1):103-111. 56. Newman JC, Bailey AD, Weiner AM: Cockayne Syndrome Group B Protein (CSB) Plays a General Role in Chromatin Maintenance and Remodeling. Proceedings of the National Academy of sciences of the United States of America 2006, 103(25):9613-9618. 57. Tacar O, Sriamornsak P, Dass CR: Doxorubicin: an Update on Anticancer Molecular Action, Toxicity and Novel Drug Delivery Systems. The Journal of Pharmacy and Pharmacology 2013, 65(2):157-170. 58. Pommier Y, Leo E, Zhang H, Marchand C: DNA Topoisomerases and their Poisoning by Anticancer and Antibacterial Drugs. Chemistry & Biology 2010, 17(5):421-433. 59. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O et al: Drug-induced Histone Eviction from Open Chromatin Contributes to the Chemotherapeutic Effects of Doxorubicin. Nature Communications 2013, 4:1908. 60. Hidaka H, Kobayashi R: Pharmacology of Protein Kinase Inhibitors. Annual Review of Pharmacology and Toxicology 1992, 32:21. 61. Caino MC, von Burstin VA, Lopez-Haber C, Kazanietz MG: Differential Regulation of Gene Expression by Protein Kinase C Isozymes as Determined by Genome-wide Expression Analysis. The Journal of Biological Chemistry 2011, 286(13):11254-11264. 62. Ray A, Fields AP, Ray BK: Activation of transcription Factor SAF Involves Its Phosphorylation by Protein Kinase C. The Journal of Biological Chemistry 2000, 275(50):39727-39733. 63. Efferth T: The Human ATP-Binding Cassette Transporter Genes: from the Bench to the Bedside. Current Molecular Medicine 2001, 1:11. 64. Peterson G, Barnes S: Genistein Inhibition of The Growth of Human Breast Cancer Cells: Independent from Estrogen Receptors and the Multi-drug Resistance Gene. Biochemical and Biophysical Research Communications 1991, 179:7. 65. Trompier D, Baubichon-Cortay H, Chang XB, Maitrejean M, Barron D, Riordon JR, Di Pietro A: Multiple Flavonoid-binding Sites Within Multidrug Resistance Protein MRP1. Cellular and Molecular Life Sciences : CMLS 2003, 60(10):2164- 2177. 66. Lania-Pietrzak B, Michalak K, Hendrich AB, Mosiadz D, Grynkiewicz G, Motohashi N, Shirataki Y: Modulation of MRP1 Protein Transport by Plant, and Synthetically Modified Flavonoids. Life Sciences 2005, 77(15):1879-1891. 67. LESLIE EM, MAO Q, OLESCHUK CJ, DEELEY RG, COLE SPC: Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) Transport and ATPase Activities by Interaction with Dietary Flavonoids. Molecular Pharmacology 2001, 59:10. 68. Pietro AD, Conseil G, Pérez-Victoriac JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault J-M, Wet Hd, Maitrejean M et al: Modulation by Flavonoids of Cell Multidrug Resistance Mediated by P-glycoprotein and Related ABC Transporters. Cellular and Molecular Life Sciences 2002, 59:16. 69. BENJAMIN CW, HIEBSCH RR, JONES DA: Caspase Activation in MCF7 Cells Responding to Etoposide Treatment. Molecular Pharmacology 1998, 53:5. 70. Allen JD, van Dort SC, Buitelaar M, Tellingen Ov, Schinkel AH: Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein. Cancer Research 2003, 63:6. 71. Litmana T, Druleyb TE, Steinc WD, Batesd SE: From MDR to MXR: New Understanding of Multidrug Resistance Systems, Their Properties and Clinical Significance. Cellular and Molecular Life Sciences 2001, 58:29. 72. Wijnholds J, Evers R, Leusden MRv, Mol CAAM, Zaman GJR, Mayer U, Beijnen JH, Valk Mvd, Krimpenfort P, Borst P: Increased Sensitivity to Anticancer Drugs and Decreased Inflammatory Response in Mice Lacking the Multidrug Resistance- associated Protein. Nature Medicine 1997, 3:5. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51617 | - |
dc.description.abstract | 伴隨著高通量微陣列技術之成熟,各式各樣統計方法及數學模型因應而生以作為微陣列數據分析之用。近年來,基因群分析方法已被廣為使用在各種分子生物研究之數據分析,由於此方法旨在全面性的分析細胞內生物功能的改變,故其在癌症基因體相關的研究中,能提供相當寶貴而重要的資訊。在此篇論文中,我們運用了基因群分析方法的概念,來提出兩個系統性的方法,分別針對拷貝數變異分析及藥物組合治療這兩個議題來作探討。
拷貝數變異被定義為 1000 個核甘酸以上的基因突變,由於其長度甚長,影響範圍甚廣,常同時影響許多致癌基因或抑癌基因,因而和癌症的發生息息相關。在此論文中,我們系統性的去探討拷貝數變異對於生物功能的影響,並分析了其與癌症病人存活率之關聯性,我們將所設計出來的分析方法運用在從 The Cancer Genome Atlas (TCGA) 所下載之乳癌病人資料,包含有拷貝數變異、基因表現、及臨床相關的資訊。從中,我們利用基因群分析方法找出了 35 個基因群和 10 個基因群分別與拷貝數增加和減少有關,同時,在此 45 個基因群中,有 44 個皆表現出與拷貝數變化相對應之基因表現變化,此外,存活分析也從與拷貝數變異相關的基因群中找出和病人存活率相關的基因群,整體而言,我們的結果顯示拷貝數變異能藉由影響基因表現而干擾生物體內之功能,並進而影響病人之存活率。 由於癌症病變的機制極其複雜性,單一抗癌藥物的治療並不一定能有效的抑制其治療之標靶及其下游的訊息傳導路徑,對該藥物的抗藥性常隨之而生,因而導致病人的癌症復發。欲解決抗藥性所導致的臨床治療失效,不同的藥物組合治療急需被測試是否具有協同作用能避免抗藥性的產生,並有效地抑制癌症細胞之增生。然而,由於已上市的抗癌藥物甚多,基於時間及成本之考量,利用細胞株實驗逐一地檢驗各種可能的藥物組合是相當沒有效率的,因此,在本篇論文中,我們提出了利用電腦預測具有協同作用之藥物組合的分析方法作為可能的解決之道。我們假設藥物協同作用是經由調控相同的生物功能,或是經由調控與某生物功能相關之幾個相似的基因,依此設計出三種預測方法,並藉由 2012 年 DREAM 競賽所提供的資料來測試這些方法的表現。結果顯示這些方法對於預測藥物協同作用有極好的準確率,其中表現最好的預測方法更勝過 DREAM 比賽中所提出的所有預測方法。此外,由於我們的預測方法是建立於基因群分析方法的概念之上,所以我們同時也能探討藥物組合是藉由何種機制來達到協同作用。我們進一步將表現最好的預測方法運用到更大的資料上,也就是來自 connectivity map 的藥物資料,以找出 更多可能具有協同作用之藥物組合。 在本篇論文中,我們證實了我們所提出的分析方法能有系統地去研究拷貝數變異以及藥物協同作用。我們希望從拷貝數變異分析中所得到的結果能夠讓我們對於癌症產生的機制有更多的了解,而我們所提出的藥物組合預測方法能夠促進藥物組合治療之發展。 | zh_TW |
dc.description.abstract | With the advances in high-throughput microarray and next-generation sequencing technologies, various statistical methods and mathematical models have been developed to comprehensively explore complex cancer genomes. Recently, a knowledge-based gene set analysis was proposed and successfully carried out remarkable findings from different layers of molecular data, such as gene expression and genomic alterations. Due to its power in detecting functional changes resulted from both significantly and modestly changed genes, gene set analysis provides biological insights into cancer genomes. In this study, we proposed two systematic analysis methods based on the concept of gene set analysis, for analyzing copy number alterations (CNAs) and predicting combinatorial drug therapy.
CNAs, defined as genomic mutations more than a thousand base pairs, affect a large number of genes simultaneously and play an essential role in tumorigenesis. In the first part of this study, we sought to systematically explore its influences on biological functions and association with patient survival. We devised an algorithm, called Gene Set analysis for Copy number Alterations (GSCA), and analyzed CNA (N = 1,045) and gene expression (N = 529) datasets of breast tumors downloaded from The Cancer Genome Atlas (TCGA). Clinical information of these samples and the identified CNA-affected gene sets were also incorporated. Thirty-five and ten gene sets showed significant enrichment in profiles of copy number gains and losses, respectively. Genes within 44 of the 45 gene sets (98%) exhibited concordant expressional changes with the status of copy numbers. On the other hand, survival analysis revealed the prognostic role of several CNA-affected gene sets. Taken together, the result showed that CNAs can disturb biological functions by altering gene expression, and thus affect the clinical outcomes of patients. Due to the complexity of cancer genome, on the other hand, patients suffered from cancer relapse caused by the occurrence of resistance to individual antitumor drugs. The development of combinatorial drug therapy is of great need since single drugs alone is not able to overcome drug resistance resulting from the continuous activation of drug target or its downstream signaling pathway. However, due to the large amount of FDA- approved drugs, it is impractical to experimentally test every possible drug pairs. We proposed a computational prediction method for drug synergy to address this issue. We hypothesized that drug pairs achieve synergy by targeting similar biological functions and similar genes in a function and validate our devised methods by the datasets provided by the DREAM consortium. The results showed that the devised prediction scores have high performance. The co-gene/GS score even outperformed the methods proposed during the DREAM challenge. In addition, the results also showed that the best performing method devised using the concept of gene set analysis is capable of investigating the underlying mechanism by which drug pairs achieve synergy. We further applied the methods to a larger dataset, the connectivity map dataset, to explore a broader range of synergistic drug combinations. Overall, in the present study we proposed two gene set-based approaches to systematically study the biological roles and clinical significance of CNAs and to predict drug synergy in breast cancer. We demonstrated that these methods can not only identify biologically well-tested results, but also reveal abundant novel candidates for future biological investigations. The findings are expected to enhance our understanding in tumorigenesis and facilitate the development of combinatorial drug therapy for cancers. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T13:41:23Z (GMT). No. of bitstreams: 1 ntu-104-R02945036-1.pdf: 1961994 bytes, checksum: 565feea276703ed670ae8d0a197eb7eb (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 誌謝…………………………………………………………………………I
中文摘要……………………………………………………………………II Abstract……………………………………………………………………IV Contents……………………………………………………………………VII List of figures………………………………………………………… X List of tables……………………………………………………………XI Chapter 1 Introduction…………………………………………………1 1.1 Microarray……………………………………………………………1 1.2 Breast cancer……………………………………………………… 1 1.3 Copy number alteration……………………………………………2 1.4 Combinatorial drug therapy………………………………………4 1.5 Gene set analysis………………………………………………… 6 1.6 Specific aims of this study…………………………………… 7 1.6.1 Gene-set approach for analyzing copy number alterations ………………………………………………………………………………8 1.6.2 A simple gene set-based analysis for drug combination prediction…………………………………………………………………8 Chapter 2 Materials and Methods ……………………………………9 2.1 Gene set approach for analyzing copy number alterations…9 2.1.1 Model overview……………………………………………………9 2.1.2 Definition of matrices…………………………………………10 2.1.3 Gene set enrichment analysis of CNAs………………………12 2.1.4 Concurrent gene expression analysis……………………… 13 2.1.5 Survival analysis……………………………………………… 14 2.2 A simple gene set-based analysis for drug combination prediction…………………………………………………………………15 2.2.1 Model overview……………………………………………………15 2.2.2 Gene set selection………………………………………………17 2.2.3 Gene set enrichment analysis using signature score … 18 2.2.4 Prediction scores……………………………………………… 20 2.2.5 Performance evaluation…………………………………………21 2.3 Datasets………………………………………………………………24 2.3.1 Datasets from The Cancer Genome Atlas…………………… 24 2.3.2 Datasets from the DREAM challenge………………………… 24 2.3.3 Connectivity map dataset…………………………………… 25 2.3.4 Gene sets from the Molecular Signature Database (MSigDB) ………………………………………………………………………………25 Chapter 3 Results ………………………………………………………26 3.1 Results of copy number alteration analysis ……………… 26 3.1.1 CNA-affected genes and gene sets……………………………26 3.1.2 Concurrent gene expression analysis.………………………30 3.1.3 Survival analysis……………………………………………… 32 3.2 Results of drug combination analysis…………………………35 3.2.1 Gene set selection………………………………………………36 3.2.2 Performance evaluation of the three scoring methods using DREAM datasets……………………………………………………………36 3.2.3 Further investigations for the co-gene/GS score ………38 3.2.4 Application to the connectivity map dataset…………… 42 Chapter 4 Discussion.………………………………………………… 44 4.1 Copy number alteration analysis……………………………… 44 4.2 Drug combination analysis……………………………………… 47 Chapter 5 Conclusion……………………………………………………53 References…………………………………………………………………55 | |
dc.language.iso | en | |
dc.title | 運用基因群概念分析癌症中拷貝數變異及藥物組合 | zh_TW |
dc.title | Gene Set-based Approaches for Analyzing Copy Number Alterations and Drug Combinations in Cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蔡孟勳,賴亮全,蕭自宏,盧子彬,蕭朱杏 | |
dc.subject.keyword | 基因群分析,拷貝數變異,藥物組合,乳癌,微陣列生物晶片, | zh_TW |
dc.subject.keyword | gene set analysis,copy number alteration,drug combination,breast cancer,microarray, | en |
dc.relation.page | 60 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-01-07 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。